[G24-14] Ublituximab (multiple sclerosis) – 2nd Addendum to Project A24-13
Last updated 01.08.2024
Project no.:
G24-14
Commission:
Commission awarded on 11.06.2024 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Health Economics
Topic:
Head and nerves
Note:
If, in the course of the discussions on a commission of the G-BA, a need for further revision arises, IQWiG presents its report in the form of an addendum. The G-BA decides on the number of patients in the SHI target population.
DOI:
https://doi.org/10.60584/G24-14
| Project no. | Title | Status |
|---|---|---|
| A24-13 | Ublituximab (multiple sclerosis) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2024-08-01 A G-BA decision was published.